Related Experiment Video
Updated: Dec 13, 2025

06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
6.0K
Fingolimod-induced immune thrombocytopenic purpura (ITP)
Loulwah Mukharesh1, Ted L Rothstein2
1Johns Hopkins University School of Medicine, Department of Neurology, Baltimore, MD, United States; George Washington University, Department of Neurology, Washington, DC, United States.
Clinical Neurology and Neurosurgery
|August 3, 2020
Abstract
No abstract available in PubMed .
Keywords:
Drug-induced immune thrombocytopenic purpuraFingolimodImmune-thrombocytopenic purpuraMultiple sclerosisNeurologyMore Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
364
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
364
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
351
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
351

